What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature

Puzenat, E.; Bronsard, V.; Prey, S.; Gourraud, Pierre-Antoine; Aractingi, S.; Bagot, Martine; Cribier, B.; Joly, P.; Jullien, D.; Maître, Michel; Paul, C.; Richard-Lallemand, M.-A.; Ortonne, Jean‐Paul; Aubin, F.

doi:10.1111/j.1468-3083.2009.03562.x

Cited by 242 publications

(222 citation statements)

References 38 publications

Supporting

Mentioning

197

Contrasting

Unclassified

Order By: Relevance

“…A systemic review performed by Puzenat et al also showed that inter-rater variation was unacceptably high for the BSA. 6 For this reason, the BSA was not recommended for assessment of the clinical severity of psoriasis. The BSA could be calculated either by the "rule of nines" method or by the number of patient's hand areas affected.…”

Section: Resultsmentioning

confidence: 99%

“…While these scales are commonly used to assess psoriasis severity in both clinical research and clinical practice, they have not been fully evaluated in terms of their validity and reliability, and no consensus exists on the best way to monitor psoriasis severity. 6,8 Despite its widespread use, the PASI has never been formally validated. Its grading has never been properly defined or standardized.…”

Section: Discussionmentioning

confidence: 99%

“…Based on systematic reviews, it appears that no single outstanding instrument has been developed for psoriasis, and none of the severity scores used for psoriasis meet all the validation criteria required for an ideal assessment instrument. 2,6 Therefore, further work is still needed to validate existing instruments and to develop new and better ones.…”

mentioning

confidence: 99%

See 2 more Smart Citations

The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment

Bożek¹,

Reich²

2017

Adv Clin Exp Med

103

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment

Bożek¹,

Reich²

2017

Adv Clin Exp Med

103

View full text Add to dashboard Cite

show abstract

“…Komponenty PASI ocenia się w 5-punktowej skali. Wskaźnik PASI stosuje się aktualnie jako złoty standard w ocenie stopnia nasilenia łuszczycy w badaniach klinicznych [20]. Obniżenie PASI o 75%, a nawet o 50% uznaje się za klinicznie istotne [21].…”

unclassified

“…PASI is a five-point scoring system that has become the gold standard in the assessment of the severity of psoriasis in clinical trials [20]. A reduction in PASI by 75% or even 50% is considered clinically significant [21].…”

mentioning

confidence: 99%

Clinical evaluation of omega-3 fatty acids in psoriasis

Adil¹,

Singh²,

Maheshwari³

2017

View full text Add to dashboard Cite

Introduction. Omega-3 fatty acids are largely derived from fish oils and are known to decrease inflammation. There have been a few small studies showing the beneficial effect of omega-3 fatty acids in psoriasis.Objective. To evaluate the efficacy of omega-3 fatty acids in conjunction with emollients in patients with mild to moderate chronic plaque psoriasis. Materials and methods.A total of 200 clinically diagnosed cases of chronic plaque psoriasis with less than 10% of body surface area involvement were recruited and divided into group A and group B. Group A was given 1,800 mg daily of omega-3 fatty acids in three divided oral doses and topical paraffin over the lesions. Group B was prescribed only topical paraffin. At the end of 12 weeks, treatment response was assessed by means of Psoriasis Area Severity Index (PASI), and by its components including area involved, erythema, induration and desquamation scores.Results. The mean PASI score changed from 7.44 to 3.96 in group A, and from 7.24 to 5.19 in group B. There was a statistically significant difference in PASI, erythema, induration, desquamation scores and area involved between the two groups after 12 weeks. Forty four (46.3%) patients in group A and 13 (13.9%) patients in group B achieved a 50% or more reduction in PASI scores.Conclusions. Omega-3 fatty acids in conjunction with topical emollients appear to reduce the severity of psoriasis with no major side effects. The combination can be a useful adjunct to other psoriasis treatments. STRESZCZENIEWprowadzenie. Kwasy omega-3 są pozyskiwane głównie z olejów rybnych. Jedną z potwierdzonych właściwości tych kwasów jest hamowanie stanu zapalnego. Przeprowadzono dotychczas kilka niewielkich badań, w których stwierdzono skuteczność kwasów tłuszczowych omega-3 w leczeniu łuszczycy.Cel pracy. Ocena skuteczności działania kwasów tłuszczowych omega-3 w skojarzeniu z emolientami w leczeniu pacjentów z łuszczycą plackowatą łagodną i umiarkowaną. Original article/Praca oryginalnaClinical evaluation of omega-3 fatty acids in psoriasis Kliniczna ocena działania kwasów tłuszczowych omega-3 w leczeniu łuszczycy Materiał i metodyka. Do badania włączono 200 pacjentów z klinicznie rozpoznaną łuszczycą obejmującą poniżej 10% powierzchni skóry. Uczestników podzielono na dwie grupy: A i B. Pacjenci z grupy A przyjmowali doustnie 1800 mg kwasów tłuszczowych omega-3 dziennie w trzech dawkach podzielonych oraz stosowali parafinę miejscowo na zmiany skórne. Pacjenci z grupy B przyjmowali wyłącznie parafinę. Po upływie 12 tygodni odpowiedź na leczenie oceniono przy wykorzystaniu wskaźnika PASI (Psoriasis Area Severity Index), na podstawie powierzchni skóry objętej zmianami oraz stopnia nasilenia rumienia, nacieku i łuski. Wyniki. Średni wskaźnik PASI zmniejszył się z 7,44 do 3,96 w grupie A oraz z 7,24 do 5,19 w grupie B. Różnica między grupami pod względem wskaźnika PASI, nasilenia rumienia, nacieku i łuski oraz powierzchni zmian skórnych po upływie 12 tygodni była istotna statystycznie. U 44 (46,3%) pacjentów z grupy A i ...

show abstract

Patient Preferences for Psoriasis Treatments

Schaarschmidt

Schmieder²,

Umar³

et al. 2011

Arch Dermatol

View full text Add to dashboard Cite

To assess patients' preferences for psoriasis treatments and to identify the effect of sociodemographic and socioeconomic characteristics on these preferences.Design: A computer-based conjoint analysis experiment was conducted to analyze the preferences of individuals with moderate or severe psoriasis for outcome attributes (probability, magnitude, and duration of benefit, as well as probability, severity, and reversibility of adverse effects) and process attributes (treatment location, frequency, duration, delivery method, and individual cost) of psoriasis treatments. Relative importance scores (RISs) for each attribute were calculated. The effect of sociodemographic (age, sex, and marital status) and socioeconomic (income and employment) characteristics and Psoriasis Area and Severity Index and Dermatology Life Quality Index scores on preferences was assessed using analysis of variance, post hoc testing, and multivariate regression analysis.Setting: Outpatient dermatology clinic at a German university medical center.Participants: Patients with moderate or severe psoriasis (N=163).Main Outcome Measure: Relative importance scores for treatment attributes. Results:The attribute considered to be most important in patients' preferences for psoriasis treatments was treatment location (RIS, 26.76), followed by probability of benefit (RIS, 23.77) and method of delivery (RIS, 23.49). The RISs for all process attributes were higher than for adverse effect-related attributes. Older individuals (Ն65 years) were less concerned about the probability of benefit (␤=−0.24; P=.005) compared with younger individuals.Conclusions: When choosing among treatment options, individuals with psoriasis appear to be willing to accept treatment-related adverse effects to obtain process attributes compatible with their personal and professional life. Incorporating preferences in shared decision making may facilitate treatment adherence and optimize outcome.

show abstract

What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature

Cited by 242 publications

References 38 publications

The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment

The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment

Clinical evaluation of omega-3 fatty acids in psoriasis

Patient Preferences for Psoriasis Treatments

Contact Info

Product

Resources

About